Aviptadil occupies an unusual place in the peptide reference landscape. Most compounds on this site arrive with a preclinical column and, at best, a scatter of small human trials. Aviptadil arrived with something different: a two-decade orphan-drug development programme, a named sponsor, and a pivotal Phase 3 that was stopped early. The failure is itself the most instructive part of its record.
What aviptadil is
Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP), a 28-amino-acid endogenous neuropeptide with wide distribution in the gut, central nervous system and lung. It has been developed under several names — RLF-100, and later Zyesami — by NeuroRx and Relief Therapeutics. VIP is reported to be highly concentrated in the lung, and the drug-development rationale has centred on the alveolar epithelium rather than on any systemic mechanism.
The compound is not a grey-market "research peptide" in origin. It holds orphan-drug designations for respiratory indications in both the US and the EU, and has an investigative history in sarcoidosis, pulmonary hypertension and acute lung injury.
The mechanism the literature supports
VIP signals through the VPAC1 receptor expressed on alveolar type II (ATII) cells. Preclinical work supports a lung-protective and immunoregulatory role: suppression of pro-inflammatory cytokine production, upregulation of pulmonary surfactant, and — in human lung cell models — inhibition of SARS-CoV-2 RNA replication. The mechanistic case was strong enough to justify a clinical programme, but mechanism is not endpoint, and the clinical record is where the picture narrows.
The pre-COVID human record
The human literature upon which the COVID-19 programme was built is small and older than the pipeline narrative implies. In an open-label Phase II study of 20 patients with histologically proven sarcoidosis, four weeks of inhaled VIP produced a significant reduction in TNF-α and an increase in a regulatory T-cell population in bronchoalveolar lavage fluid — an immunoregulatory signal in a small, uncontrolled cohort, not a clinical-outcome result. A separate 2020 case report described VIP use in checkpoint-inhibitor-induced pneumonitis. Additional evidence for inhaled aviptadil in pulmonary arterial hypertension exists as small, open-label work. None of this amounts to a randomised, adequately powered clinical-outcome dataset in any respiratory indication.
The COVID-19 pivot
The pandemic reframed aviptadil as a cytokine-storm therapy. A multicentre, placebo-controlled trial randomised 196 patients with COVID-19 respiratory failure 2:1 to three days of intravenous aviptadil or placebo, with a primary endpoint of being alive and free from respiratory failure at day 60. Reporting of that trial was mixed: one synthesis described no significant overall change versus placebo alongside a survival signal, while others reported a statistically significant benefit once baseline severity and site of care were controlled for. That disagreement — over a trial the authors themselves acknowledged was underpowered — is the crux of why the result was never decisive.
The ACTIV-3b (TESICO) halt
The decisive dataset came from the NIH-sponsored ACTIV-3b (TESICO) platform trial in critical COVID-19, which tested intravenous aviptadil and remdesivir alone and in combination against placebo. In May 2022, after reviewing data on roughly 460 patients, the trial's independent data and safety monitoring board recommended stopping further randomisation to aviptadil for futility. The primary 90-day six-category ordinal endpoint was not met (interim p = 0.56), and the secondary 90-day mortality endpoint was likewise unsupportive: 37% mortality in the aviptadil arm versus 36% on placebo. No new safety concerns emerged; the known effects of diarrhoea and hypotension were managed within protocol. The FDA subsequently declined an emergency use authorisation.
An inhaled formulation explored for prevention of COVID-19-related ARDS was terminated early for recruitment difficulties, with results unpublished.
How to grade the evidence
On this site's four-tier system, aviptadil sits at Limited. There is a genuine randomised trial record and a clear mechanistic rationale, which distinguishes it from purely anecdotal compounds — but the best-powered trial was halted for futility, the positive signals come from small or contested analyses, and no respiratory indication has a replicated, adequately powered clinical-outcome result. A single halted Phase 3 does not license confident claims in either direction; it tells you the effect is not large enough to detect in a well-run trial of that size.
The UK regulatory position
Aviptadil holds no UK marketing authorisation for any respiratory indication. Where a peptide is supplied for human use without a marketing authorisation, that engages the Human Medicines Regulations 2012 and the Medicines Act 1968, and MHRA enforcement has repeatedly targeted the marketing of unlicensed peptides with medicinal claims. The "research use only" label describes supply for laboratory investigation; it is not a route to human use, and it does not neutralise the medicines rules. Nothing in this article is consumption, dosing or self-administration guidance, and Peptide Data does not provide any.
What the record does and does not support
It supports this: aviptadil is a synthetic VIP with a real, if unsuccessful, drug-development history; VIP has plausible lung-directed immunoregulatory activity in preclinical and small human studies; and the class did not demonstrate clinical benefit in critical COVID-19 respiratory failure at a trial scale capable of testing it. It does not support claims that aviptadil treats, cures or prevents any respiratory condition — in research use or otherwise.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.